Total: $307.5M | ||||
|
||||
Company |
Location |
Date |
Amt. (M) |
Details |
|
||||
Advanced Accelerator Applications S.A. |
Saint Genis Pouilly, France |
7/25 |
€40 ($57.4) |
AAA closed a $57.4M funding round; Dompé Group participated in the latest round and now holds a 7.7% stake |
BioMimetix Inc. |
Unknown |
7/22 |
$2 |
Omni Bio Pharmaceutical Inc., of Denver, picked up a 25% equity stake in recently formed BioMimetix |
Cevec Pharmaceuticals GmbH |
Cologne, Germany |
7/26 |
€6 ($8.6) |
Cevec raised $8.6M in a financing round led by NRW.BANK and Creathor Venture Fonds; the firm's current investors, a group of private and institutional investors and ERP Startfonds of KfW bank also participated |
Coronado Biosciences Inc. |
New York |
7/7 |
$25.8 |
Coronado closed a $25.8M Series C round led by National Securities Corp. |
Cytochroma Inc. |
Markham, Ont. |
7/27 |
$1 |
Cytochroma closed an equity investment from the Investment Accelerator Fund of Ontario |
glcare Pharma Inc. |
Montreal |
7/22 |
$7 |
glcare raised $7M in a Series A round co-led by Forbion Capital Partners and Genesys Capital |
Immune System Therapeutics Ltd. |
Sydney, Australia |
7/25 |
A$2.6 ($2.8) |
Immune System raised $2.8M in a placement of 5.2M shares priced at A50 cents apiece |
Novira Therapeutics Inc. |
Radnor, Pa. |
7/27 |
$2.5 |
Novira completed a second round of seed funding to bring its early financing total to about $2.5M; the financing was led by Delaware Crossing Investor Group, the Mid-Atlanta Angel Group Fund II and Robin Hood Ventures; existing investor BioAdvance also participated |
Peloton Therapeutics Inc. |
Dallas |
7/28 |
$18 |
Peloton raised $18M in a Series A round led by The Column Group, with participation from Remeditex Ventures and Peter O'Donnell Jr. |
Pharminox Ltd. |
Nottingham, UK |
7/8 |
£1.5 ($2.4) |
Pharminox raised $2.4M from existing shareholders and new private investors |
SARcode Bioscience Inc. |
Brisbane, Calif. |
7/18 |
$44 |
SARcode raised $44M in the Series B round led by Sofinnova Ventures; other investors were Rho Ventures, Alta Partners and Clarus Venture Partners |
Sorbent Therapeutics Inc. |
Sunnyvale, Calif. |
7/5 |
$36 |
Sorbent expanded its Series B round by $36M, for a deal total of $53M; the round was led by Novartis Venture Funds, and was joined by Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem |
SpringLeaf Therapeutics Inc. |
Boston |
7/11 |
$4 |
SpringLeaf secured an additional $4M in a second closing of its Series B round from new investor Excel Venture Management, bringing the total round to $19M |
Tarsa Therapeutics Inc. |
Philadelphia |
7/13 |
$24.5 |
Tarsa raised $24.5M through a second round; investors were MVM Life Science Partners, Quaker BioVentures, Novo A/S and Unigene Laboratories Inc. |
Vantia Therapeutics Ltd. |
Southampton, UK |
7/7 |
$6.5 |
Vantia raised $6.5M in a Series B financing; investors were Novo A/S, SV Life Sciences and MVM Life Science Partners |
Verastem Inc. |
Boston |
7/15 |
$32 |
Verastem raised $32M in a Series B round led by Advanced Technology Ventures and Astellas Venture Management; other investors were Longwood Founders Fund, Bessemer Venture Partners, Cardinal Partners and MPM Capital |
Visionary Pharmaceuticals Inc. |
San Diego |
7/28 |
ND |
Visionary raised undisclosed seed round investments from a consortium of angel investors |
Zafgen Inc. |
Cambridge, Mass. |
7/7 |
$33 |
Zafgen raised $33M through Atlas Venture and Third Rock Ventures |
|
||||
Notes: Currency conversions are based on exchange rates at the time of the deal. ** Denotes the date the item ran in BioWorld International. The date indicated refers to the BioWorld Today issue in which the news item can be found. ND = Not disclosed. |